doi: 10.1038/srep35113 8 BakalovD.LilovL
however, the safety and efficacy of such therapy have not been systematically evaluated Risk factors of statinfibrate-related myopathy include advanced age, female gender, low BMI, renal disease, diabetes mellitus, hypothyroidism, multisystem disease, fever, surgery, trauma, and strenuous physical exercise The likelihood and/or severity of myopathy also depend on pharmacologic properties of the statin and the fibrate, such as their enzymatic metabolism or excretion and/or their protein-regulated intercellular transport Fenofibrate or fenofibric acid may be fibrates of choice for statinfibrate therapy because, according to pharmacokinetic and postmarketing data, they are associated with lower risks of myopathy (versus gemfibrozil) This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 12 print issues and online access 189,00 per year only 15,75 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF
In summary, prolotherapy stands as a currently used therapy in the EDS toolkit, particularly suited for hypermobile joints causing chronic pain
Autism Res 9 , 350375 (2016)
